The specter of generic challenges has long loomed over copyright’s famous drug, Viagra, triggering questions about the outlook of related drug ventures. While early times saw substantial gains, the exclusivity end has created the path for cheaper substitutes, likely reducing earnings and presenting a genuine danger for shareholders looking for st